We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
BELLUS Health Inc | NASDAQ:BLU | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 14.74 | 14.74 | 14.75 | 0 | 01:00:00 |
|
Canada
(Province or Other Jurisdiction of Incorporation or
Organization) |
| |
2834
(Primary Standard Industrial
Classification Code Number (if Applicable)) |
| |
Not applicable
(I.R.S. Employer Identification Number (if
Applicable)) |
|
|
Sebastien Roy
Davies Ward Phillips & Vineberg LLP 1501 McGill College Ave Montréal, Québec H3A 3N9 Canada Telephone: (514) 841-6493 |
| |
Roberto Bellini
BELLUS Health Inc. 275 Armand-Frappier Blvd. Laval, Québec H7V 4A7 Canada Telephone: (450) 680-4551 |
| |
Mitchell S. Bloom
Danielle Lauzon Goodwin Procter LLP 100 Northern Avenue Boston, Massachusetts 02210 United States Telephone: (617) 570-1000 |
|
| | | | | 1 | | | |
| | | | | 1 | | | |
| | | | | 1 | | | |
| | | | | 3 | | | |
| | | | | 5 | | | |
| | | | | 6 | | | |
| | | | | 9 | | | |
| | | | | 9 | | | |
| | | | | 10 | | | |
| | | | | 23 | | | |
| | | | | 36 | | | |
| | | | | 36 | | | |
| | | | | 37 | | | |
| | | | | 38 | | | |
| | | | | 39 | | | |
| | | | | 39 | | | |
| | | | | 43 | | | |
| | | | | 49 | | | |
| | | | | 50 | | | |
| | | | | 50 | | | |
| | | | | 50 | | | |
| | | | | 51 | | | |
| | | | | 76 | | | |
| | | | | 76 | | | |
| | | | | 76 | | | |
| | | | | 77 | | | |
| | | | | 77 | | | |
| | | | | C-1 | | |
ALL PARTICIPANTS — INTENT TO TREAT PATIENT POPULATION (N=67)
|
| ||||||||||||
DOSE
|
| |
PLACEBO-
ADJUSTED REDUCTION IN AWAKE COUGH FREQUENCY |
| |
P-VALUE
|
| ||||||
25 mg BID
|
| | | | -11% | | | | | | p=0.14 | | |
50 mg BID
|
| | | | -6% | | | | | | p=0.46 | | |
100 mg BID
|
| | | | -8% | | | | | | p=0.41 | | |
200 mg BID
|
| | | | -17% | | | | | | p=0.09 | | |
Pre-specified Subgroup — PARTICIPANTS with awake cough frequency at ≥ 20 coughs/hour (n=54)
|
| ||||||||||||
DOSE
|
| |
PLACEBO-
ADJUSTED REDUCTION IN AWAKE COUGH FREQUENCY |
| |
P-VALUE
|
| ||||||
25 mg BID
|
| | | | -20% | | | | | | p=0.0010 | | |
50 mg BID
|
| | | | -18% | | | | | | p=0.0186 | | |
100 mg BID
|
| | | | -19% | | | | | | p=0.0320 | | |
200 mg BID
|
| | | | -27% | | | | | | p=0.0026 | | |
PRE-SPECIFIED SUBGROUP — PARTICIPANTS WITH AWAKE COUGH FREQUENCY AT OR ABOVE BASELINE
MEDIAN (≥ 32.4 COUGHS/HOUR; N=34) |
| ||||||||||||
DOSE
|
| |
PLACEBO-
ADJUSTED REDUCTION IN AWAKE COUGH FREQUENCY |
| |
P-VALUE
|
| ||||||
25 mg BID
|
| | | | -28% | | | | | | p=0.0005 | | |
50 mg BID
|
| | | | -28% | | | | | | p=0.0003 | | |
100 mg BID
|
| | | | -30% | | | | | | p=0.0014 | | |
200 mg BID
|
| | | | -32% | | | | | | p=0.0006 | | |
|
(Signed) Roberto Bellini
President and Chief Executive Officer |
| |
(Signed) Ramzi Benamar
Chief Financial Officer |
|
|
On behalf of the Board of Directors
|
| |||
|
(Signed) Dr Francesco Bellini
Director |
| |
(Signed) Pierre Larochelle
Director |
|
|
Exhibit
Number |
| |
Description
|
|
| 4.1 | | | | |
| 4.2 | | | | |
| 4.3 | | | | |
| 4.4 | | | | |
| 4.5 | | | | |
| 4.6 | | | | |
| 4.8 | | |
Material change report of the Registrant dated July 13, 2022 regarding the announcement of a positive End-of-Phase 2 meeting with the U.S. Food and Drug Administration (“FDA”) and its CALM Phase 3 program for BLU-5937 in refractory chronic cough (incorporated by reference to Exhibit 99.2 to the Registrant’s report on Form 6-K with the SEC on July 13, 2022).
|
|
| 5.1* | | | Consent of KPMG LLP. | |
| 5.2* | | | Consent of Davies Ward Phillips & Vineberg LLP. | |
| 6.1* | | | Powers of Attorney (included on the signature page of this Registration Statement). | |
|
107*
|
| | Calculation of Filing Fee Tables. | |
| | | | BELLUS HEALTH INC. | | |||
| | | |
By:
/s/ Roberto Bellini
Name: Roberto Bellini
Title: President and Chief Executive Officer |
|
|
Signature
|
| |
Title
|
| | ||
|
/s/ Roberto Bellini
Roberto Bellini
|
| | President, Chief Executive Officer and Director (principal executive officer) | | | ||
|
/s/ Ramzi Benamar
Ramzi Benamar
|
| | Chief Financial Officer (principal financial and accounting officer) | | | ||
|
/s/ Francesco Bellini
Francesco Bellini
|
| | Chair | | | | |
|
/s/ Youssef L. Bennani
Youssef L. Bennani
|
| | Director | | | | |
|
/s/ Franklin M. Berger
Franklin M. Berger
|
| | Director | | | | |
|
/s/ Clarissa Desjardins
Clarissa Desjardins
|
| | Director | | | ||
|
/s/ Pierre Larochelle
Pierre Larochelle
|
| | Director | | | | |
|
/s/ Joseph Rus
Joseph Rus
|
| | Director | | | | |
|
/s/ William Mezzanotte
William Mezzanotte
|
| | Director | | | | |
| | | | PUGLISI & ASSOCIATES | | |||
| | | | By: | | |
/s/ Donald J. Puglisi
Name: Donald J. Puglisi
Title: Managing Director |
|
1 Year BELLUS Health Chart |
1 Month BELLUS Health Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions